Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison - PubMed (original) (raw)
Review
. 2019 Jan;143(1):190-200.e20.
doi: 10.1016/j.jaci.2018.08.031. Epub 2018 Sep 8.
Affiliations
- PMID: 30205189
- DOI: 10.1016/j.jaci.2018.08.031
Free article
Review
Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison
William Busse et al. J Allergy Clin Immunol. 2019 Jan.
Free article
Erratum in
- Corrigendum.
[No authors listed] [No authors listed] J Allergy Clin Immunol. 2019 Jun;143(6):2336. doi: 10.1016/j.jaci.2019.04.010. J Allergy Clin Immunol. 2019. PMID: 31176383 No abstract available.
Abstract
Background: Three anti-IL-5 pathway-directed therapies are approved for use in patients with severe eosinophilic asthma (SEA); however, no head-to-head comparison data are available.
Objective: We sought to compare the efficacy of licensed doses of mepolizumab, benralizumab, and reslizumab in patients with SEA, according to baseline blood eosinophil counts.
Methods: This indirect treatment comparison (ITC) used data from a Cochrane review and independent searches. Eligible studies were randomized controlled trials in patients aged 12 years or greater with SEA. End points included annualized rate of clinically significant exacerbations and change from baseline in Asthma Control Questionnaire score and FEV1. An ITC was performed in patients with Asthma Control Questionnaire scores of 1.5 or greater and stratified by baseline blood eosinophil count.
Results: Eleven studies were included. All treatments significantly reduced the rate of clinically significant exacerbations and improved asthma control versus placebo in all blood eosinophil count subgroups. Mepolizumab reduced clinically significant exacerbations by 34% to 45% versus benralizumab across subgroups (rate ratio ≥400 cells/μL: 0.55 [95% CI, 0.35-0.87]; ≥300 cells/μL: 0.61 [95% CI, 0.37-0.99]; and ≥150 cells/μL: 0.66 [95% CI, 0.49-0.89]; all P < .05) and by 45% versus reslizumab in the 400 cells/μL or greater subgroup (rate ratio, 0.55 [95% CI, 0.36-0.85]; P = .007). Asthma control was significantly improved with mepolizumab versus benralizumab (all subgroups: P < .05) and versus reslizumab in the 400 cells/μL or greater subgroup (P = .004). Benralizumab significantly improved lung function versus reslizumab in the 400 cells/μL or greater subgroup (P = .025).
Conclusions: This ITC of the licensed doses suggests that mepolizumab was associated with significantly greater improvements in clinically significant exacerbations and asthma control compared with reslizumab or benralizumab in patients with similar blood eosinophil counts.
Keywords: Benralizumab; indirect treatment comparison; mepolizumab; network meta-analysis; reslizumab; severe eosinophilic asthma.
Copyright © 2018 GlaxoSmithKline. Published by Elsevier Inc. All rights reserved.
Comment in
- Indirect Treatment Comparisons and Biologics.
Mauger D, Apter AJ. Mauger D, et al. J Allergy Clin Immunol Pract. 2019 Jan;7(1):131-133. doi: 10.1016/j.jaip.2018.11.008. J Allergy Clin Immunol Pract. 2019. PMID: 30598174 No abstract available. - Indirect treatment comparisons and biologics.
Mauger D, Apter AJ. Mauger D, et al. J Allergy Clin Immunol. 2019 Jan;143(1):84-86. doi: 10.1016/j.jaci.2018.11.005. J Allergy Clin Immunol. 2019. PMID: 30612667 No abstract available. - Reply.
Gunsoy NB, Bratton DJ, Albers FC, Busse W. Gunsoy NB, et al. J Allergy Clin Immunol. 2019 Mar;143(3):1267-1268. doi: 10.1016/j.jaci.2018.11.023. Epub 2019 Jan 11. J Allergy Clin Immunol. 2019. PMID: 30639066 No abstract available. - Indirect treatment comparison of asthma biologics fraught with methodology issues.
Bourdin A, Molinari N. Bourdin A, et al. J Allergy Clin Immunol. 2019 Mar;143(3):1266-1267. doi: 10.1016/j.jaci.2018.11.024. Epub 2019 Jan 11. J Allergy Clin Immunol. 2019. PMID: 30639069 No abstract available.
Similar articles
- Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
Casale TB, Pacou M, Mesana L, Farge G, Sun SX, Castro M. Casale TB, et al. J Allergy Clin Immunol Pract. 2019 Jan;7(1):122-130.e1. doi: 10.1016/j.jaip.2018.08.036. Epub 2018 Sep 11. J Allergy Clin Immunol Pract. 2019. PMID: 30217529 - Anti-IL5 therapies for asthma.
Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Farne HA, et al. Cochrane Database Syst Rev. 2017 Sep 21;9(9):CD010834. doi: 10.1002/14651858.CD010834.pub3. Cochrane Database Syst Rev. 2017. PMID: 28933516 Free PMC article. Updated. Review. - Anti-IL-5 therapies for asthma.
Farne HA, Wilson A, Milan S, Banchoff E, Yang F, Powell CV. Farne HA, et al. Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD010834. doi: 10.1002/14651858.CD010834.pub4. Cochrane Database Syst Rev. 2022. PMID: 35838542 Free PMC article. Review. - Anti-IL-5 therapies for chronic obstructive pulmonary disease.
Donovan T, Milan SJ, Wang R, Banchoff E, Bradley P, Crossingham I. Donovan T, et al. Cochrane Database Syst Rev. 2020 Dec 8;12(12):CD013432. doi: 10.1002/14651858.CD013432.pub2. Cochrane Database Syst Rev. 2020. PMID: 33295032 Free PMC article. - Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study.
Numata T, Miyagawa H, Nishioka S, Okuda K, Utsumi H, Hashimoto M, Minagawa S, Ishikawa T, Hara H, Araya J, Kuwano K. Numata T, et al. BMC Pulm Med. 2020 Aug 3;20(1):207. doi: 10.1186/s12890-020-01248-x. BMC Pulm Med. 2020. PMID: 32746787 Free PMC article.
Cited by
- Clara cell 10 (CC10) protein attenuates allergic airway inflammation by modulating lung dendritic cell functions.
Xu YD, Cheng M, Mao JX, Zhang X, Shang PP, Long J, Chen YJ, Wang Y, Yin LM, Yang YQ. Xu YD, et al. Cell Mol Life Sci. 2024 Jul 30;81(1):321. doi: 10.1007/s00018-024-05368-z. Cell Mol Life Sci. 2024. PMID: 39078462 Free PMC article. - Ratio of plasma IL-13/TNF- ∝ and CXCL10/CCL17 predicts mepolizumab and omalizumab response in asthma better than eosinophil count or immunoglobulin E level.
Akenroye A, Nopsopon T, Hacker JJ, Laidlaw TM. Akenroye A, et al. Sci Rep. 2024 May 6;14(1):10404. doi: 10.1038/s41598-024-60864-3. Sci Rep. 2024. PMID: 38710930 Free PMC article. - Long-term multicenter comparison shows equivalent efficacy of monoclonal antibodies in severe asthma therapy.
Kayser MZ, Suhling H, Fuge J, Hinze CA, Drick N, Kneidinger N, Behr J, Taube C, Welte T, Haasler I, Milger K. Kayser MZ, et al. BMC Pulm Med. 2024 Mar 21;24(1):149. doi: 10.1186/s12890-024-02964-4. BMC Pulm Med. 2024. PMID: 38515071 Free PMC article. - [Unmet Needs in Severe Allergic Asthma].
Delgado J, Navarro A, Álvarez-Gutiérrez FJ, Cisneros C, Domínguez-Ortega J. Delgado J, et al. Open Respir Arch. 2023 Nov 1;5(4):100282. doi: 10.1016/j.opresp.2023.100282. eCollection 2023 Oct-Dec. Open Respir Arch. 2023. PMID: 38053757 Free PMC article. Spanish. - Unanswered questions on the use of biologics in pediatric asthma.
Nieto A, El-Sayed ZA, Gómez RM, Hossny E, Jiu-Yao W, Kalayci Ö, Morais-Almeida M, Phipatanakul W, Pitrez PM, Pozo Beltrán CF, Xepapadaki P, Papadopoulos NG. Nieto A, et al. World Allergy Organ J. 2023 Nov 3;16(11):100837. doi: 10.1016/j.waojou.2023.100837. eCollection 2023 Nov. World Allergy Organ J. 2023. PMID: 38020283 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical